Lung cancer remains the leading cause of cancer mortality both globally and in Taiwan. Advances in systemic therapies have substantially improved outcomes for patients with lung cancer. Experts from six leading medical societies in Taiwan collaborated to develop this guideline on the pharmacological management of advanced lung cancer. This guideline focuses on first- and second-line treatments, including chemotherapy, targeted therapy, and immunotherapy, based on tumor histology, molecular profile, PD-L1 expression level, and disease stage. It aims to improve lung cancer outcomes by providing a clear and localized treatment framework tailored to the clinical practice setting in Taiwan. This paper reports specifically on the pharmacological treatment of advanced non-squamous cell lung cancer with actionable oncogenic drivers. Recommendations are categorized according to levels of evidence, from large randomized controlled trials (level of evidence LoE I) to expert opinion (LoE V).
Wu et al. (2026) studied this question.